Esomeprazole after endoscopic sleeve gastroplasty to preserve sleeve integrity

Phase 4, randomised, open-label trial of esomeprazole in obesity (2 arms), sponsored by Policlinico Gemelli. Primary endpoints: Proportion of patients with intact endoscopic sleeve gastroplasty at 6 months and Proportion of patients with intact endoscopic sleeve gastroplasty at 12 months. Started Oct 2021; status: active.